Human Endogenous Retroviruses in Clear Cell Renal Cell Carcinoma: Biological Functions and Clinical Values

Wenjun Cao 1,2
Ran Kang 1
Yining Xiang 1
Jidong Hong 1

1Department of Oncology, Xiangya Hospital, Central South University, Changsha, Hunan, People’s Republic of China; 2Department of Urology, The First Affiliated Hospital of University of South China, Hengyang, Hunan, People’s Republic of China

Abstract: Human endogenous retroviruses (HERVs) form an important part of the human genome, commonly losing their coding ability and exhibiting only rare expression in healthy tissues to promote the stability of the genome. However, overexpression of HERVs has been observed in various malignant tumors, including clear cell renal cell carcinoma (ccRCC), and may be closely correlated with tumorigenesis and progression. HERVs may activate the interferon (IFN) signaling pathway by a viral mimicry process to enhance antitumor immune responses. There is increasing interest in the diagnostic and prognostic value of HERVs in cancers, and they may be candidate targets for tumor immunotherapy. The review will introduce the biological functions of HERVs in ccRCC and their clinical value, especially in regard to immunotherapy.

Keywords: clear cell renal cell carcinoma, human endogenous retroviruses, immunotherapy, long terminal repeat, biomarker

Introduction

Millions of years ago, retroviruses invaded and integrated into the cells of human hosts, and the resulting genomic components are known as human endogenous retroviruses (HERVs), which are vertically inherited by offspring and persist throughout human evolution. HERVs form a vital component of the human genome, accounting for ~8%. To date, more than 50 HERV groups have been found and divided into classes I–III. For example, HERV-E and HERV-H belong to class I, whereas HERV-K belongs to class II. 1 Full-length HERVs comprise gag, pol, env and two gene regulatory sequences on both sides of the 5’ and 3’ ends, namely, a long terminal repeat (LTR) (Figure 1). 2 HERVs often lost coding ability but exist permanently in the genome due to deletion, mutation and hypermethylation. 3 There are only a few genes that encode functional proteins such as HERV-K and HERV-W 3,4. HERV-W encodes Syncytin proteins, which are essential for placental syncytiotrophoblast cell development. 4 Inactivation of HERVs can also be attributed to solo-LTRs, which are generated by non-allelic homologous recombination between the 5’ and 3’ LTRs. 5,6 LTRs make great contributions to the complexity of the genome in providing promoters, enhancers, repressors, poly A signals and alternative splicing sites for human genes. The majority of HERVs reside in human genomic DNA as solo-LTRs, some of which retain primary transcriptional regulatory motifs and hence a gene regulatory capacity. 6,7

A substantial body of research has indicated that dysregulated expression of HERVs is strongly correlated with the occurrence and development of clear cell renal cell carcinoma.
Full-length HERV

5' | LTR | gag | pol | env | LTR | 3'

Solo-LTR

5' | LTR | 3'

Figure 1: The structure of HERVs. Full-length HERVs comprise gag, pol, and env and 5' and 3' LTRs. Solo-LTRs are generated by non-allelic homologous recombination between the 5' and 3' LTRs. The majority of HERVs reside in human genomic DNA as solo-LTRs.

Biological Functions of HERVs in ccRCC

HERVs in the Occurrence and Progression of ccRCC: Mainly Related to LTRs

One mechanism of tumorigenesis is that the reactivation of LTRs drives ectopic expression. Recent research on the renal cell carcinoma (RCC) genome shows that reactivation of the hypoxia-inducible factor (HIF)-dependent dormant promoters embedded in LTRs mainly upregulates the expression of the stem cell transcription factor Pou5f1 in ccRCC patients, which promotes tumorigenesis by affecting transcriptional dysregulation. It is worth noting that self-renewing RCC stem cells may be a small group of tumor cells in patients that can produce the Pou5f1 protein. Similarly, abnormal activation of LTR promoters in Hodgkin lymphoma (HL) patients can drive the expression of the proto-oncogene colony-stimulating factor-1 receptor (CSF1R), while healthy controls do not exhibit LTR-driven CSF1R transcripts. Reactivation of LTRs is also controlled by the level of DNA methylation. Recently, pioneering research found that the HERV-E 5' LTR, located on chromosome 6q, is hypomethylated in ccRCC and that the combination of HIF and a HIF response element (HRE) of the 5' LTR can lead to overexpression of HERV-E transcripts and tumor antigen CT-RCC-1 in tumor tissues but not in normal tissues. Sporadic ccRCC has somatic mutations in the VHL gene, resulting in reduced degradation of HIF. The regulation of the VHL gene is particularly important for HERV-E activation. The VHL gene was introduced into a VHL-deficient ccRCC cell line, resulting in the inhibition of HERV-E expression. The B7/CD28 family members are important modulators of T-cell responses in the tumor immunity process, such as programmed cell death-1 (PD-1), and cytotoxic T-lymphocyte-associated protein 4 (CTLA4). HERV-H LTR-associating protein 2 (HHLA2), a novel member of the B7 family, is related to the inhibition of the T-cell receptor. A recent study indicated that HHLA2 shows increased expression in ccRCC tissues compared to normal tissues and that
HHLA2 may promote the progression of ccRCC by inactivating efficient antitumor T-cells and increasing tumor angiogenesis.19

HERVs affect tumorigenesis and prognosis in a variety of different ways. Some studies considered Np9, encoded by HERV-K type 1, as a novel viral oncogene that can activate several signaling pathways that confer proliferative and survival advantages to stem/progenitor leukemia cells, such as the β-catenin, AKT, Notch1 and ERK pathways.27,28 Studies on breast cancer, melanoma and germ cell tumors have shown that HERVs are oncogenic and act by activating the ERK1/2 cell signaling pathway.9,10 Abnormal expression of HERV elements has been detected in prostate cancer,29 breast cancer,30 lung cancer31 and colorectal cancer32 and is closely related to the occurrence and development of these tumors, but the underlying molecular mechanisms require further elucidation.

Immunomodulatory Effects of HERVs
For a long time, the immunomodulatory effects of HERVs have attracted much attention. Healthy people have low or no expression of HERVs and can generally tolerate the basal expression of HERVs to avoid autoimmune reactions. However, the expression of HERVs often increases in autoimmune diseases and tumors. Derived from retroviruses, HERVs and their products have high immunogenicity that may activate the antitumor immune response.33–35 The interferon (IFN) response is inducible by the double-stranded RNA (dsRNA) and single-stranded RNA (ssRNA) arising from HERVs in a process called “viral mimicry”.36,37 The dsRNA and ssRNA can activate its vital sensors including toll-like receptors (TLRs), RLRs retinoic acid-inducible gene I (RIG-I), and melanoma differentiated associated gene 5 (MDA 5), resulting in the expression of type I IFN by activating NF-κB, which can induce IFN-regulatory factor-3 and 7 (IRF-3 and IRF-7).36–39 IFNs can increase the expression of MHC type I on tumor cells, which may promote T-cells to recognize tumor cells (Figure 2).36,37 Anti-HERV-K gag and env antibodies have been detected in melanoma patients, which proves that HERV-K proteins can activate the humoral immune response, and the HERV-K antigen is the target of CTLs and is presented by HLA-A2 of HLA class I on melanoma cells.40,41 Tumor antigen CT-RCC-1 acts as the target antigen of cytotoxic T lymphocytes (CTLs) to increase immune infiltration in ccRCC patients.8 Smith et al42 discussed the mechanisms underlying the immune regulation of HERVs in ccRCC: (i) HERV 4700, located on chromosome 6q, is also known as CT-RCC HERV-E, which can trigger antitumor immunological effects as a direct target of the immune system or a new biomarker of anti-programmed death receptor 1 (aPD1) responsiveness, and (ii) the authors divided HERVs into 2 groups, group 2 HERVs may increase the immunosuppression of tumor microenvironment by downregulating the RIG-I-like pathway through an unknown

![Figure 2](image-url). HERVs can up-regulate tumor immune signal and trigger subsequent antitumor immune by a viral mimicry process. The double-stranded RNA (dsRNA) and single-stranded RNA (ssRNA) arising from HERVs can activate toll-like receptors (TLRs), RLRs retinoic acid-inducible gene I (RIG-I), and melanoma differentiated associated gene 5 (MDA 5), resulting in the activation of NF-κB. Consequently, NF-κB induces the production of type I interferon (IFN) by activating IFN-regulatory factor-3 and 7 (IRF-3 and IRF-7). IFNs can increase the expression of MHC type I on tumor cells to promote T-cells to recognize tumor cells. This process is called viral mimicry.

Notes: Data from these studies.36–39
mechanism. There are significant differences between the biological effects of different types of HERVs. HERV-H is important for tumor immune evasion and metastasis.\(^{43}\) HHLA2 may inactivate efficient antitumor T-cells and promote ccRCC tumor cell escape from immune attack.\(^{19}\) In short, the majority of HERVs are beneficial for activating the antitumor effect, but the tumor microenvironment may weaken this effect.

**Potential Clinical Values of HERVs in ccRCC**

Developing novel anticancer therapeutic targets depends upon identifying target antigens that exhibit differential expression between normal and tumor tissues. Overexpression of HERVs has been observed in various malignant tumors, and many studies show that HERVs have potential clinical values in the early diagnosis, prognostic prediction and immunotherapy of tumors. The lack of specific biomarkers and effective therapeutic targets are serious obstacles to improving the prognosis of ccRCC patients. The overexpression of HERVs and CTL responses against HERVs in ccRCC patients highlight HERVs as biomarkers for early diagnosis, targets for immunotherapy and predictors of prognosis.

**HERVs Acting as Candidate Targets for Immunotherapy**

**HERVs Acting as Tumor Vaccine Targets**

Effective tumor-associated antigens (TAAs) that can be recognized by T-cells have attracted great attention due to their ability to minimize the risk of autoimmunity. However, the lack of identified TAAs is still a major obstacle in developing tumor vaccines. To date, therapeutic vaccines for RCC have not achieved significant clinical efficacy;\(^{44}\) thus, it is necessary to develop novel specific TAAs as vaccine targets. HERVs are usually not expressed in noncancerous populations, and tumor vaccines based on HERVs may induce long-lasting CTL responses for the clearance of HERV-overexpressing cancer cells.

Previous studies have indicated the differential expression of HERVs between normal and tumor tissues and CTL responses against HERVs that highlight HERVs as targets for preventive and therapeutic tumor vaccines in ccRCC.\(^{5}\) Renal cancer vaccination directed against HERV-K gag and env protein has achieved preliminary success in animal models.\(^{45,46}\) Intravenous injection of cells expressing the HERV-K gag protein into a syngeneic murine renal cancer model can cause formation of pulmonary metastases. Vaccination with the recombinant vaccinia virus expressing the HERV-K gag protein can reduce the growth of pulmonary metastases.\(^{45}\) A previous study by the same author showed that prophylactic vaccination against the HERV-K env protein reduces tumor formation and metastasis of RCC, but vaccination safety and effectiveness in humans have not yet been evaluated.\(^{46}\) HERV-E env and LTRs are source of antigens recognized by T-cells in ccRCC patients; thus, the HERV-E env and LTRs products may act as vaccine targets.\(^{8,24,35}\) Moreover, studies have suggested that HERV-H Xp22.3 should be included in clinical vaccination programs for colorectal tumors, but further work is still required to estimate safety.\(^{47}\) To improve the safety of vaccines, future studies should develop tumor vaccines against single HERV site targets.

**HERVs as Specific Targets for Adoptive Cell Therapy (ACT) and Monoclonal Antibody (mAb) Therapy**

ACT and mAb therapy are effective cancer immunotherapy modalities. The common goals of these therapies are to reduce toxicity and increase efficacy by improving the specificity of T-cell responses. Isolated from ccRCC patients with tumor regression after hematopoietic stem cell transplantation (HSCT), CTLs can specifically recognize HERV-E env and LTRs expression products, which are promising targets for ACT and mAb therapy in ccRCC.\(^{24}\)

The safety and efficacy of these therapies have been confirmed in other tumor (Table 1). HERV-K env-specific chimeric antigen receptor T (CAR-T) cells can reduce primary tumor and metastatic burden of murine xenograft model by recognizing and killing HERV-K env-overexpressing melanoma cells without attacking normal cells.\(^{48}\) Zhou et al\(^{19}\) observed a notable reduction or no metastasis to multiple organs in a murine breast cancer model after HERV-K env-specific CAR-T cell treatment, and they confirmed that HERV-K env products act as cancer-promoting proteins to promote oncogenesis related to the activation of Ras–ERK and MDM2 signaling. Wang-Johanning’s team verified that the anti-HERV-K env protein-specific mAb can suppress human breast cancer cell proliferation and limit tumor growth in breast tumor-bearing mice.\(^{34}\) As a result, they proposed HERV-specific mAbs as effective antitumor treatments earlier. In a phase Ib clinical trial involving 270 multiple sclerosis (MS) patients, GNBAC1, a humanized mAb targeting the HERV-W env protein, reduced brain atrophy, and showed
a good safety with no hypersensitivity response or infusion reactions and uninduced immunogenicity.\textsuperscript{50,51}

Epigenetic Therapy and Immune Checkpoint Inhibitor (ICI) Combinatory Treatment

Epigenetic therapy is an emerging strategy in anticancer therapy. DNA methyltransferase inhibitors (DNMTis), including azacitidine, decitabine and guadecitabine, are widely effective agents of epigenetic therapy that have exhibited remarkable clinical efficacy in hematological malignancies.\textsuperscript{52} DNMTis can reactivate HERVs to express dsRNA which can activate IFN signaling pathway by a viral mimicry process to up-regulate tumor immune signal and trigger subsequent antitumor immune responses (Figure 2).\textsuperscript{37,53,54} Roulois et al\textsuperscript{55} proved that the lasting anti-tumor effect of low-dose 5-aza-2-deoxycytidine (5-AZA-CdR) on colorectal cancer-initiating cells (CICs) induced by the production of dsRNA activates the viral mimicry process. The anti-tumor effect of 5-AZA-CdR can be simulated by transfecting dsRNA into CICs.\textsuperscript{55} PD ligand 1 (PD-L1)-PD-1 or CD80/86-CTLA-4 interactions can induce the immunosuppressive activities of immune checkpoints which can be disrupted by ICIs to promote T-cell activation.\textsuperscript{56} The viral mimic effect can also upregulate PD-L1 and CLAT4 to improve the sensitivity of ICIs.\textsuperscript{37,53} When used alone, both decitabine and ICI showed poor efficacy in a murine ovarian cancer model, but anti-CTLA-4 therapy showed enhanced efficacy when combined with decitabine.\textsuperscript{57} ICIs rarely induce a complete response (CR) in relapsed or refractory classical HL, but, in a clinical trial, all 5 patients treated with 5-azacitidine followed by ICI achieved a CR, while only 2 of the other 4 patients who received the ICI alone achieved a CR.\textsuperscript{58}

Based on the above evidences that DNMTis can activate IFN signal pathway and enhance the efficacy of ICIs, accumulating clinical trials are addressing the safety and efficacy of DNMTis and ICI combinatory treatment (Table 2). The poor prognosis of ccRCC patients is closely related to resistance to targeted therapy and insensitivity to immunotherapy, but HERVs have raised hopes for novel therapies. At present, the combination of durvalumab and guadecitabine is being evaluated in a multicenter phase Ib/II clinical trial for advanced renal cancer (ClinicalTrials.gov identifier: NCT03308396). The final results are expected to demonstrate the effectiveness and safety of combinatory treatment in ccRCC patients. In addition, high HERV expression is related to a poor prognosis in ccRCC patients who may receive greater benefit from combinatory treatment.\textsuperscript{42}

### Roles of HERVs in ccRCC Early Diagnosis and Prognosis Prediction

Due to the lack of specific clinical manifestations in the early stage, the discovery of novel specific biomarkers, ideally measurable by noninvasive methods, is urgently required for early detection of ccRCC and for improving prognosis. Some findings have reported that HERV-K is overexpressed in early-stage breast tumor tissues but hardly expressed in healthy control samples raising the idea that HERV-K may be biomarker for the early detection of breast cancer.\textsuperscript{59} While prostate-specific antigen (PSA) is used as a biomarker for the early detection of prostate cancer, the overall sensitivity of the serum PSA level decreases with aging. In a study involving 294 prostate cancer patients and 135 healthy males, the HERV-K gag mRNA abundance in the blood was significantly higher in the patients with prostate cancer than in the healthy controls, and further results suggested HERV-K as potential biomarkers for the early detection of prostate cancer; the joint detection of HERV-K and PSA may improve diagnostic efficiency in prostate cancer.\textsuperscript{60} Moreover, HERV-K env can serve as a potential diagnostic biomarker of ovarian cancer.\textsuperscript{61} Given the above, HERVs are potential tumor-specific biomarkers and more studies are needed to

<table>
<thead>
<tr>
<th>Disease Type</th>
<th>CAR-T Cell/mAb</th>
<th>Efficacy</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>Melanoma</td>
<td>HERV-K env-specific CAR-T cell</td>
<td>Reduction of primary tumor and metastatic burden of murine model</td>
<td>[48]</td>
</tr>
<tr>
<td>Breast cancer</td>
<td>HERV-K env-specific CAR-T cell</td>
<td>Notable reduction or no metastasis to multiple organs in murine model</td>
<td>[34]</td>
</tr>
<tr>
<td>Breast cancer</td>
<td>Anti-HERV-K env protein-specific mAb</td>
<td>Blocking human breast cancer cell proliferation and limiting tumor growth in breast tumor-bearing mice</td>
<td>[42]</td>
</tr>
<tr>
<td>MS</td>
<td>Anti-HERV-W env protein humanized mAb</td>
<td>Reducing brain atrophy of patients and well tolerated</td>
<td>[50,51]</td>
</tr>
</tbody>
</table>

Abbreviations: CAR-T, chimeric antigen receptor T; mAb, monoclonal antibody; MS, multiple sclerosis.
Table 2 Clinical Trials Combining Epigenetic and Immune Therapy

<table>
<thead>
<tr>
<th>DNMTi</th>
<th>ICI</th>
<th>Condition</th>
<th>Phase</th>
<th>NCT Number</th>
</tr>
</thead>
<tbody>
<tr>
<td>Azacitidine</td>
<td>Atezolizumab</td>
<td>MDS</td>
<td>I</td>
<td>NCT02508870</td>
</tr>
<tr>
<td></td>
<td>Avelumab</td>
<td>AML, B-cell lymphoma</td>
<td>I, II</td>
<td>NCT03390296, NCT02953561, NCT02951156</td>
</tr>
<tr>
<td></td>
<td>Durvalumab</td>
<td>Colorectal carcinoma, ovarian cancer, breast cancer, T-cell lymphoma, MDS, head and neck cancer, NSCLC</td>
<td>I, II</td>
<td>NCT02811497, NCT0161223, NCT02775903, NCT03019003, NCT02117219, NCT02281084, NCT02250326</td>
</tr>
<tr>
<td></td>
<td>Ipilimumab</td>
<td>Leukemia, MDS</td>
<td>II</td>
<td>NCT02530463, NCT02979720</td>
</tr>
<tr>
<td></td>
<td>Nivolumab</td>
<td>Leukemia, AML, Osteosarcoma, NSCLC, MDS</td>
<td>I, II</td>
<td>NCT02599649, NCT02530463, NCT03825367, NCT04128020, NCT02397720, NCT03628029, NCT01928576, NCT03259516</td>
</tr>
<tr>
<td></td>
<td>Pembrolizumab</td>
<td>MDS, pancreas cancer, Melanoma, colorectal cancer, AML, NSCLC, ovarian cancer</td>
<td>I, II</td>
<td>NCT03094637, NCT03264404, NCT02816021, NCT02959437, NCT02260440, NCT02845297, NCT04284787, NCT02546896, NCT02900560</td>
</tr>
<tr>
<td></td>
<td>Tremelimumab</td>
<td>Head and neck cancer, MDS</td>
<td>I, II</td>
<td>NCT03019003, NCT02117219</td>
</tr>
<tr>
<td>Decitabine</td>
<td>Avelumab</td>
<td>AML</td>
<td>I</td>
<td>NCT03395873</td>
</tr>
<tr>
<td></td>
<td>SHR-1210</td>
<td>HL, B-cell lymphoma</td>
<td>I, II</td>
<td>NCT03250962, NCT03346642</td>
</tr>
<tr>
<td></td>
<td>Ipilimumab</td>
<td>AML, MDS</td>
<td>II</td>
<td>NCT02890329</td>
</tr>
<tr>
<td></td>
<td>Nivolumab</td>
<td>AML, MDS, lung cancer</td>
<td>I, II</td>
<td>NCT03358719, NCT04277442, NCT02664181</td>
</tr>
<tr>
<td></td>
<td>Pembrolizumab</td>
<td>AML, lymphoma, MDS, breast cancer, NSCLC</td>
<td>I, II</td>
<td>NCT02996474, NCT03240211, NCT03445858, NCT03969446, NCT02957968, NCT03233724</td>
</tr>
<tr>
<td></td>
<td>Tremelimumab</td>
<td>NSCLC</td>
<td>I</td>
<td>NCT03019003, NCT02117219</td>
</tr>
<tr>
<td>Guadecitabine</td>
<td>Atezolizumab</td>
<td>Leukemia, AML, MDS</td>
<td>I, II</td>
<td>NCT02935361, NCT02892318</td>
</tr>
<tr>
<td></td>
<td>Durvalumab</td>
<td>Kidney cancer, ccRCC, hepatocellular carcinoma, cholangiocarcinoma, pancreatic cancer, SCLC</td>
<td>I, II</td>
<td>NCT03308396, NCT03257761, NCT03085849</td>
</tr>
<tr>
<td></td>
<td>Ipilimumab</td>
<td>Melanoma, NSCLC</td>
<td>I, II</td>
<td>NCT02608437, NCT04250246</td>
</tr>
<tr>
<td></td>
<td>Nivolumab</td>
<td>Melanoma, NSCLC, colorectal carcinoma</td>
<td>I, II</td>
<td>NCT04250246, NCT03576963</td>
</tr>
<tr>
<td></td>
<td>Pembrolizumab</td>
<td>Lung Cancer, fallopian tube carcinoma, ovarian carcinoma, primary peritoneal carcinoma, NSCLC</td>
<td>I, II</td>
<td>NCT03220477, NCT02901899, NCT02998567</td>
</tr>
<tr>
<td></td>
<td>Tremelimumab</td>
<td>SCLC</td>
<td>I</td>
<td>NCT03085849</td>
</tr>
</tbody>
</table>

Abbreviations: DNMTi, DNA methyltransferase inhibitor; ICI, immune checkpoint inhibitor; MDS, myelodysplastic syndrome; AML, acute myeloid leukemia; NSCLC, non-small-cell lung carcinoma; HL, Hodgkin lymphoma; ccRCC, clear cell renal cell carcinoma; SCLC, small cell lung cancer.

determine the diagnostic values of these biomarkers in ccRCC, especially in early diagnosis.

The most common system for evaluating tumor progression and prognosis is the TNM staging system; however, it is insufficient for malignant tumors. Recently, there is gaining interest for prognostic values of HERVs in cancers (Table 3). High endogenous retrovirus (ERV) I expression is associated with poor patient survival in RCC. As mentioned before, LTRs play a key role in upregulating Pou5f1 expression, which is related to the progression of RCC and poor overall survival. Overexpressed HERV-K env is related to metastasis and a poor prognosis for breast cancer patients; thus, HERV-K env can be used as a new prognostic predictor for breast cancer patients. A study found that melanoma patients with anti-HERV-K antibodies had a significantly reduced overall survival rate. They reported that serological HERV-K responses might be an independent prognostic biomarker for a decreased survival rate in melanoma patients at AJCC stage I–III. Moreover, ERV3-2
overexpression in responders compared with nonresponders in a research involving 24 patients with metastatic ccRCC receiving PD-1/PD-L1 blockade suggested a possible role for HERVs as predictors of the antitumor immune response in renal cancers.64 The abnormal expression of HHLA2 has prognostic significance in gastric cancer and bladder urothelial carcinoma.65,66 The increased expression of HHLA2 in ccRCC tissues results in a shorter overall survival indicating that HHLA2 may be a potential prognostic marker of ccRCC.19

**Conclusion**

With the discovery of abnormal expression of HERVs and anti-HERV antibodies in various tumors, the correlation between HERVs and cancers that has been suggested does not reveal a cause–effect relationship but provides evidence for HERVs as potential targets for cancer diagnosis and therapy. Great effort is needed to unravel possible contact and discover the molecular mechanisms involving HERVs in cancers.

HERV elements and expression products are intricately connected to cancers. The efficient reactivation ofLTRs poses a significant threat to genome stability and serves vital biological roles in the occurrence and progression of ccRCC.8,19,21 HERVs may activate the IFN signaling pathway through a viral mimicry process to enhance antitumor immune responses (Figure 2).36-39 Epigenetic therapy may increase the sensitivity of cancer patients to ICIs through this process.37,53 Therefore, DNMTis and ICI combinatorial treatment brings hope to cancer patients, especially for patients with poor response to ICIs. HERV-K-directed vaccination has achieved preliminary success in animal models.45 HERV-specific ACT and mAb therapy have shown efficiency in vitro experiments for melanoma and breast cancer and might represent promising novel therapeutic approaches in ccRCC, but clinical trials are required in the future for the assessment of the safety and efficacy of new therapies. Tumor immunotherapy targeting HERVs may be a key to developing breakthroughs in ccRCC therapy, especially in advanced-stage tumors.34,48,49 In addition, the great majority of the studies performed to date, both for disease etiopathogenesis and diagnosis, measured the expression of an entire HERV group. To link HERVs and cancer or biomarker usage to specific locus, future research should focus on the identification of single HERV sites.

**Funding**

This study was supported by the innovative research and development projects for the Development and Reform Commission of HUNAN Province of China (2019-412) and Hunan Provincial Natural Science Foundation of China (2019JJ80015).

**Disclosure**

The authors report no conflicts of interest in this work.

**References**


27. Bhardwaj et al., 2015.


30. Frank et al., 2003.

31. Kayho et al., 2018.

32. Madeira et al., 2020.


34. Chiappinelli et al., 2018.

35. Alcazar et al., 2019.

36. Schiavetti et al., 2018.


